An exciting example of this approach is the use of Lutetium-177-labeled PSMA (Lu-PSMA), which has shown promise in treating metastatic prostate cancer by delivering targeted radiation to PSMA-expressing tumor cells. Here, FOLH1 is linked to metastatic prostate carcinoma.